Ibuprofen, diclofenac, naproxen, indomethacin, ketorolac, nimesulide and piroxicam -in addition to etoricoxib and rofecoxib- are pain relievers that are associated with “…a greater risk of hospitalization due to heart failure.”
Published in the British Medical Journal, these were the findings of the research conducted by Proyecto SOS, financed by the European Community. Over a 10-year period, the study analyzed a database of the official patient records of people from Holland, Italy, German and the United Kingdom (1999 – 2010).
These products all belong to the family of nonsteroidal anti-inflammatory drugs (NSAIDs) and are widely used to control pain and inflammation, the majority of which are even used without a prescription.
Etoricoxib and rofecoxib both known as COX-2 inhibitors were developed in the ‘90s with the objective of achieving the same results as other pain relievers, yet being less toxic on the digestive system. According to the study, the effects of these drugs on the heart, “…could depend on a complex interaction of pharmacological properties, including duration and extent of platelet inhibition, extent of blood pressure increase, and properties possibly unique to the molecule.”
Researchers are encouraging doctors to be aware of these results given the “…considerable impact that cardiovascular diseases have on global public health.”